TransCode Therapeutics Secures New Financing to Extend Runway

TransCode Therapeutics ( (RNAZ) ) has issued an announcement.

On April 6, 2026, TransCode Therapeutics entered into a financing arrangement with institutional investor Yorkville that combines up to $6 million in pre-paid advances via convertible promissory notes and a three-year Standby Equity Purchase Agreement for up to $14 million in common stock, subject to trading, registration and shareholder-approval conditions. The structure, which includes exchange caps, ownership limits and discounted conversion features, is intended to extend TransCode’s cash runway into late 2027 or early 2028 while giving the company discretion over timing and size of equity draws, though it also introduces potential dilution for existing shareholders as notes convert and additional stock is sold.

The company also reported that, as part of its October 8, 2025 acquisition of ABCJ, LLC from DEFJ, LLC, it has now paid required payment-in-kind dividends on its Series A preferred stock, issuing additional preferred shares on April 6, 2026 to DEFJ and its financial adviser Tungsten Advisors. Together, the flexible equity facility and the preferred-share PIK issuance strengthen near-term liquidity and support the planned Phase 2a trial of lead candidate TTX-MC138, while concentrating more of the economic upside in sophisticated accredited investors and potentially reshaping the company’s capital structure over time.

The most recent analyst rating on (RNAZ) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on TransCode Therapeutics stock, see the RNAZ Stock Forecast page.

Spark’s Take on RNAZ Stock

According to Spark, TipRanks’ AI Analyst, RNAZ is a Neutral.

The score is primarily constrained by weak financial performance (no revenue, widening losses, and ongoing cash burn), with limited valuation support due to continued losses. Offsetting factors include constructive near-term technical momentum and positive corporate developments around the pipeline and planned Phase 2a work, though high volatility and stretched oscillators temper the technical contribution.

To see Spark’s full report on RNAZ stock, click here.

More about TransCode Therapeutics

TransCode Therapeutics, Inc. is a Boston-based clinical-stage biotechnology company focused on immuno-oncology and RNA therapies for high-risk and advanced cancers. Its lead candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a biomarker of metastasis, and is supported by a broader pipeline of first-in-class candidates designed to mobilize the immune system against cancer cells.

TTX-MC138 has shown delivery and pharmacodynamic activity in a Phase 0 trial and met its safety endpoint in a Phase 1a study, where it was well tolerated. A Phase 2a clinical trial of TTX-MC138 in metastatic cancer is planned to begin in the second quarter of 2026, underscoring TransCode’s focus on advancing novel RNA-based oncology treatments through mid-stage clinical development.

Average Trading Volume: 215,715

Technical Sentiment Signal: Sell

Current Market Cap: $8.22M

Find detailed analytics on RNAZ stock on TipRanks’ Stock Analysis page.